-
| Exchange | NASDAQ |
|---|---|
| CurrencyCode | USD |
| ISIN | None |
| Sector | None |
| Industry | None |
| Market Cap | None |
|---|---|
| PE Ratio | nan |
| Target Price | nan |
| Dividend Yield | nan% |
| Beta | nan |
Lite Strategy, Inc. a clinical-stage pharmaceutical company, focuses on the development of various therapies for the treatment of cancer. It develops ME-344, an intravenous small molecule inhibitor mitochondrial oxidative phosphorylation to treat human epidermal growth factor receptor 2 negative breast cancer, colorectal cancer, and solid tumors. It also engages in digital asset treasury management. The company was formerly known as MEI Pharma, Inc. and changed its name to Lite Strategy, Inc. in September 2025. Lite Strategy, Inc. was incorporated in 2000 and is based in San Diego, California.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for LITS using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025